Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

The importance of clinician engagement in the HTA process


Published on

Join Alexandra Chambers & oncologist Dr. Craig Earle with CADTH's pan-Canadian Oncology Drug Review (pCODR) as they discuss the opportunities for clinicians to participate in the process and be part of the system, and how clinician input can help to inform cancer drug funding recommendations to enhance patient outcomes for Canadians.

3Sixty Public Affairs' Bill Dempster moderated this interactive webinar that included opportunities for participants to participate in polling and ask questions.

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

The importance of clinician engagement in the HTA process

  1. 1. The importance of clinician engagement in the HTA process Alexandra Chambers & Dr. Craig Earle CADTH pan-Canadian Oncology Drug Review Program
  2. 2. Agenda • About CADTH’s pan-Canadian Oncology Drug Review (pCODR) Program • Overview of the pCODR process • Clinician participation in pCODR program • Value of Engagement: a clinician’s perspective
  3. 3. Polling Question #1 • Participants attending this session – Please select: a) Patient Representative b) Clinician c) Industry Member d) Consultant e) Government/HTA organization f) Other
  4. 4. CADTH’s pCODR Program • Assess cancer drugs and make recommendations to ministries of health and provincial cancer agencies, to guide their drug funding decisions • Designed to bring consistency and clarity to assessment of cancer drugs by looking at clinical evidence, cost-effectiveness and patient perspectives • Committed to transparency and the need to be accountable to patients and public, and responsive to industry
  5. 5. Polling Question #2 • How much do you know about the public drug funding and approval process in Canada? – Please select: a) Good knowledge b) Fair, a refresher would be helpful c) This is new information
  6. 6. 6 Drug Access—Who Does What Health Canada Regulator (Effect & safety) CDR (CADTH) pCODR (CADTH) Quebec (INESSS) HTA (Assess value) Pan Canadian Pharmaceutical Alliance (pCPA) Price negotiator F/P/T Ministries of Health and Cancer Agencies Decision maker/ funder
  7. 7. Clinician Engagement in pCODR • Each drug review includes a Clinical Guidance Panel of 3-5 expert clinicians to provide clinical interpretation and context of drug under review • pCODR Expert Review Committee (pERC) includes several clinician members in addition to patient members, health economists, and pharmacists • In February 2016, Registered Clinician input/feedback was introduced
  8. 8. pCODR Review Process Provincial Advisory Group Submitter Patient Advocacy Group Registered Clinician Review Team Registered Clinician Provincial Advisory Group Patient Advocacy Group pCODR Expert Review Committee Submitter INPUT SUBMISSION REVIEW DELIBERATIONS FEEDBACK Initial Recommendation Final Recommendation Review Team: • Clinical Guidance Panel • Economic Guidance Panel • Health Research Methodologist
  9. 9. Why include registered clinician input? Objectives: 1. Collaboration and Representation – Expands participation to involve oncologists in the community – Enables cancer specialists to provide input on value of a particular drug and its place in therapy 2. Value-added information – Provides insight into regional and local issues from a practice setting perspective for Review Team and pERC
  10. 10. How can clinicians participate? • Must register with pCODR – one time registration process • Eligibility: – you are an actively practising oncologist – you are a member of a provincial cancer agency or similar body or a national cancer organization and • Note: If a clinician is selected as a pERC member or for the Clinical Guidance Panel to review a specific drug product – that clinician will not be eligible to provide input or feedback on that specific review
  11. 11. Polling Question #3 • Have you registered to provide input on a pCODR drug review? – Please select: a) Yes b) No
  12. 12. How is clinician input submitted? • Email notifications are sent 1 month in advance of drug submission to pCODR • Deadline for input is 10 business days after the submission is received • Registered clinician input template to complete • Information received from registered clinicians is summarized and incorporated in pCODR reports Note: CADTH has discretion to remove any information that may be out of scope of the review
  13. 13. More on submitting clinician input… • Input can be submitted by an individual oncologist or • One joint input can be submitted by a group of oncologists: – only one input form is submitted but all contributing oncologists are identified – lead oncologist to indicate input is joint effort – all oncologists in the group must register – all must provide own declaration of conflict of interests • Declaration of conflict of interests must be provided with each input submitted • Clinician input and feedback, including COI will be publicly posted on CADTH website – applies to all participants in pCODR process
  14. 14. Polling Question #4 • For those who have registered, have you provided input on a pCODR drug review? – Please select: a) Yes b) No
  15. 15. Polling Question #5 • If you have registered, please indicate why you have not yet provided input – Please select: a) A relevant drug has not been reviewed b) A relevant drug was reviewed, but I did not have enough experience prescribing it to make a meaningful contribution c) A relevant drug was reviewed, but I did not have time to submit input d) A relevant drug was reviewed, but I found the process for completing the template to be too complicated e) I didn’t know about the registered clinician process f) None of the above – other reasons
  16. 16. How can clinicians respond to a pERC recommendation? • Through registered clinician feedback • If a registered clinician provides input, he/she can also provide feedback on the initial pERC recommendation • Template for feedback • 10 business days to provide feedback after initial pERC recommendation is posted on CADTH website
  17. 17. pCODR Expert Review Committee Clinician input presented, used in deliberations & reflected in recommendations How is clinician input used? CADTH Review Team Clinician input used to inform protocol & reports Public Drug Plans Shared with participating jurisdictions and shared at
  18. 18. Why should clinicians engage in pCODR? • Clinician participation in pCODR process – contributes to shaping the availability of cancer drugs based on clinical evidence – shared experiences provides a way for clinicians to be part of the system to enhance patient outcomes for Canadians • For more information about pCODR’s clinician engagement process, please see: feedback
  19. 19. Polling Question #6 • Did you find this session helpful in understanding about the clinician engagement process through pCODR? – Please select: a) Yes b) No
  20. 20. Thank You & Questions
  21. 21. @CADTH_ACMTS Connect With Us
  22. 22. Canadian Cancer Survivor Network Contact Info Canadian Cancer Survivor Network 1750 Courtwood Crescent, Suite 210 Ottawa, ON K2C 2B5 Telephone / Téléphone : 613-898-1871 E-mail or Web site Instagram: @survivornet_ca Twitter: @survivornetca Facebook: Pinterest: